bluebird bio (BLUE) LentiGlobin is Here To Stay, Roth Capital Says; PT Cut to $165

bluebird bio (BLUE) Price Target Reduced to $149 at BofA/Merrill Lynch

November 6, 2015 7:34 AM EST

BofA/Merrill Lynch maintained a Buy rating on bluebird bio (NASDAQ: BLUE) but lowered its price target to $149.00 (from $241.00). Analyst Ying Huang reduced the addressable market for BB305 to 50% in severe thalassemia patients ineligible for stem cell transplant and lowered approval probability to 42%... More

Too Earlier to Write Off bluebird bio's (BLUE) LentiGlobin in Subset - Cowen

November 5, 2015 3:44 PM EST

Cowen maintained an Outperform rating on bluebird bio (NASDAQ: BLUE). Shares declined after it announced data from its ongoing clinical studies of LentiGlobin will be highlighted in oral and poster presentations at the ASH meeting. In the view of analyst Eric Schmidt, it is far too early to conclude that LentiGlobin treatment will not lead to major benefits in beta0/beta0 patients.

"BLUE shares have come under pressure largely because beta0/beta0 subjects who make no endogenous beta chain Hb (the severest of beta-thal patients) have not achieved transfusion independence. In HGB-204,... More

bluebird bio (BLUE) LentiGlobin 'Does Work', Maxim Group Says

November 5, 2015 1:06 PM EST

Maxim Group analyst Jason McCarthy reiterated a Buy rating and $190 price target on bluebird bio (NASDAQ: BLUE) following today's ASH abstracts. He higlights that SCD and Beta Thal are not the same, exclaiming "it does work."

McCarthy highlighted:

bluebird reported 3Q with a net loss of $42M. The company has $900M in cash,... More

bluebird bio (BLUE) Most Severe Beta-Thal Patients Presenting Challenges, Wedbush Comments; PT Lowered to $165

November 5, 2015 12:39 PM EST

Wedbush analyst David Nierengarten reiterated an Outperform rating on bluebird bio (NASDAQ: BLUE) following today's ASH abstract update but cut his price target to $165.00 (from $222.00). The analyst said the most severe beta-thal patients are presenting challenges.

Nierengarten commented, "Three LentiGlobin abstracts at ASH: Continued transfusion independence in majority of beta-thal patients but most severe patients not there (yet). Our view is that there is increased risk to the programs clinical/regulatory approval timing and... More

'Not Time to Hit Panic Button' on bluebird bio (BLUE), Oppenheimer Says

November 5, 2015 12:23 PM EST

Oppenheimer analyst Wendy Lam is out with her second defense of bluebird bio (NASDAQ: BLUE) today amid the 20% sell-off. Lam said "it is not time to hit the "panic button."

Lam commented, "In ASH abstracts published this morning, BLUE provided an update on... More